Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12057095 | 0.83 | BRD4 (0.31) | — | |
| SCHEMBL14898349 | 0.83 | MGLL (0.31) | — | |
| SCHEMBL10074884 | 0.81 | MGLL (0.31) | — | |
| SCHEMBL13369180 | 0.81 | BRD4 (0.30) | — | |
| SCHEMBL13347914 | 0.80 | MGLL (0.30) | — | |
| SCHEMBL12057094 | 0.79 | MAPT (0.35) | GAA | |
| SCHEMBL327851 | 0.79 | BRD4 (0.32) | — | |
| SCHEMBL2570463 | 0.79 | MGLL (0.33) | GLA | |
| SCHEMBL6699078 | 0.79 | MGLL (0.33) | GLAGAA | |
| SCHEMBL17777287 | 0.79 | MGLL (0.33) | GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |
| US-20120238621-A1 | Oligomer-Calcimimetic Conjugates and Related Compounds | NEKTAR THERAPEUTICS (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | NEKTAR THERAPEUTICS (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110237524-A1 | POLYMER CONJUGATES OF AOD-LIKE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110171166-A1 | POLYMER CONJUGATES OF OSTEOCALCIN PEPTIDES | NEKTAR THERAPEUTICS | 2011-07-14 | — | — | US | disclosed |
| US-20110171165-A1 | POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES | NEKTAR THERAPEUTICS | 2011-07-14 | — | — | US | disclosed |
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171163-A1 | POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES | NGLY1, VIP, IAPP | GLA 2903/4885GAA 1484/4885 |
| US-20110237524-A1 | POLYMER CONJUGATES OF AOD-LIKE PEPTIDES | NGLY1, OCIAD1, TAP1 | GLA 3137/4885GAA 1221/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | GLA 289/4885GAA 371/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | GLA 2752/4885GAA 710/4885 |
| US-20120238621-A1 | Oligomer-Calcimimetic Conjugates and Related Compounds | CALCR, CALCB, CALCA | GLA 1111/4885GAA 1268/4885 |
| US-20110171166-A1 | POLYMER CONJUGATES OF OSTEOCALCIN PEPTIDES | SOST, PTMS, ALPP | GLA 68/4885GAA 1124/4885 |
| US-20110171165-A1 | POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES | OGFR, OGFRL1, OPRL1 | GLA 3153/4885GAA 2443/4885 |
| US-20120100096-A1 | CONJUGATES PF SMALL-INTERFERING NUCLEIC ACIDS | SLC19A1, FOLR1, SLC46A1 | GLA 3802/4885GAA 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.